Applied Genetic Technologies Corporation (NASDAQ: AGTC) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitabiliy and institutional ownership.

Profitability

This table compares Applied Genetic Technologies Corporation and Galmed Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Applied Genetic Technologies Corporation 17.61% 6.62% 4.49%
Galmed Pharmaceuticals N/A -130.85% -96.94%

Volatility & Risk

Applied Genetic Technologies Corporation has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 2.56, meaning that its stock price is 156% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Applied Genetic Technologies Corporation and Galmed Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Genetic Technologies Corporation 0 3 6 0 2.67
Galmed Pharmaceuticals 0 0 4 0 3.00

Applied Genetic Technologies Corporation currently has a consensus target price of $14.63, indicating a potential upside of 195.45%. Galmed Pharmaceuticals has a consensus target price of $11.75, indicating a potential upside of 137.85%. Given Applied Genetic Technologies Corporation’s higher possible upside, research analysts plainly believe Applied Genetic Technologies Corporation is more favorable than Galmed Pharmaceuticals.

Valuation & Earnings

This table compares Applied Genetic Technologies Corporation and Galmed Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Applied Genetic Technologies Corporation $43.24 million 2.07 $8.04 million $0.41 12.07
Galmed Pharmaceuticals $735,000.00 81.78 -$15.85 million ($1.39) -3.55

Applied Genetic Technologies Corporation has higher revenue and earnings than Galmed Pharmaceuticals. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Applied Genetic Technologies Corporation, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

61.5% of Applied Genetic Technologies Corporation shares are owned by institutional investors. Comparatively, 8.0% of Galmed Pharmaceuticals shares are owned by institutional investors. 2.5% of Applied Genetic Technologies Corporation shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Applied Genetic Technologies Corporation beats Galmed Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Applied Genetic Technologies Corporation Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company’s Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.